Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis 2021; 21: 637–46—In this Article, the legend to figure 1 should have stated: “Due to a sudden increase in interest from potential participants, parallel enrolment at several sites, and an oversight in the trial software, 27 of the 132 people who reached target enrolment after the planned size of 375 people was reached received a first dose and 26 of them a second dose. They were not included in further safety or immunogenicity trial data, but were monitored for safety with 3 people reporting injection site pain and 1 person a tingling sensation after the first dose, and 1 person drowsiness, 2 people headache, and 1 person injection site pain after the second dose. No serious adverse events occurred.” This correction has been made to the online version as of Jan 18, 2023.
Correction to Lancet Infect Dis 2021; 21: 637–46
Issue date 2023 Mar.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.